Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.33 |
| ▸ | GOT1 | P17174 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 3/20 | 0.32 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | PHGDH | O43175 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL806552 | 0.85 | GAA (0.34) | GPR52GOT1GAADHFRPHGDH | |
| SCHEMBL806554 | 0.85 | GOT1 (0.36) | GPR52GOT1GAADHFRPHGDH | |
| SCHEMBL14933295 | 0.85 | BRD4 (0.38) | GOT1GAADHFRPHGDH | |
| SCHEMBL13983476 | 0.78 | HSP90AA1 (0.53) | — | |
| SCHEMBL9925250 | 0.77 | GOT1 (0.36) | GPR52GOT1GAA | |
| SCHEMBL13983147 | 0.77 | HSP90AA1 (0.43) | GAAGFERKMT2A | |
| SCHEMBL806553 | 0.77 | HSP90AA1 (0.40) | GOT1GAADHFR | |
| SCHEMBL12180125 | 0.76 | GOT1 (0.39) | GPR52GOT1GAAPHGDHMEN1 | |
| SCHEMBL806551 | 0.71 | HSP90AA1 (0.54) | — | |
| SCHEMBL12180265 | 0.71 | HSP90AA1 (0.44) | GAAGFERKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013006864-A2 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-01-10 | — | — | WO | disclosed |
| WO-2012162584-A1 | COMBINATION THERAPY OF HSP90 INHIBITORY COMPOUNDS WITH CHK INHIBITORS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-29 | — | — | WO | disclosed |
| WO-2011133521-A2 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUNDS AND A VEGF INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2011-10-27 | — | — | WO | disclosed |